{"@id":"https://bioecon.ru/technology/open-access-vaccine-adjuvants/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://en.bioecon.ru/technology/open-access-vaccine-adjuvants/","json":"https://en.bioecon.ru/api/v1/technology/open-access-vaccine-adjuvants/index.json"},"id":"open-access-vaccine-adjuvants","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/botanical-solution-inc/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/vaxxinova-norway/","https://bioecon.ru/companies/archisen/","https://bioecon.ru/companies/paris-biofoundry-france/","https://bioecon.ru/companies/bio-base-europe-pilot-plant/","https://bioecon.ru/companies/vaksindo-animal-health/"]},"maturity":7,"name":"Open-Access Vaccine Adjuvants","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Synthetic QS-21 saponin production"},{"n":2,"title":"Liposomal and nano-emulsion formulation"},{"n":3,"title":"TLR agonist synergistic blending"},{"n":4,"title":"Equitable access \u0026 GMP distribution"}],"summary":"A sovereign open-access innovation infrastructure synthesizing and standardizing clinical-grade modern vaccine adjuvants—including synthetic saponin analogs (QS-21), squalene-in-water emulsions, and synthetic TLR4/TLR7/8 agonists—under equitable, non-exclusive terms to democratize global vaccine development.","url":"/technology/open-access-vaccine-adjuvants/","verified":"2026-11-22"}